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Expression signature of glycidamide, the reactive metabolite of
the widespread food carcinogen acrylamide
Abstract
Recent findings of acrylamide in foods have sparked renewed interest in assessing human health hazards
associated with the exposure to this vinyl compound. Acrylamide is tumorigenic at high doses in
rodents, but cancer risk projections in the human population remain problematic since the molecular
pathogenesis of acrylamide at the low level of dietary uptake is not understood. The present thesis is
concerned with the question of whether transcriptional responses may amplify the known genotoxicity
of acrylamide. Therefore, we used high-density DNA microarrays and PCR validations to assess
genomewide messenger profiles induced in human cells by acrylamide and glycidamide, its more
reactive metabolite. The expression changes are characterized by the up-regulation of cytoprotective
factors including the glutathione system, carbonyl reductases and various antioxidants. Low-dose
experiments indicate that epoxide hydrolase 1 represents the most sensitive biomarker for the internal
glycidamide exposure. At higher concentrations, glycidamide induces markers of tumor progression
such as steroid hormone activators, regulators of nuclear factor-κB, growth stimulators and apoptosis
inhibitors. Concomitantly, growth suppressors and cell adhesion molecules are suppressed. The main
implication of these findings for risk assessment is that transcriptional signatures associated with tumor
cell progression may be expected only at higher doses that exceed the range of ordinary dietary
exposure.
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1.  SUMMARY 
              
 
Recent findings of acrylamide in foods have sparked renewed interest in assessing human 
health hazards associated with the exposure to this vinyl compound. Acrylamide is 
tumorigenic at high doses in rodents, but cancer risk projections in the human population 
remain problematic since the molecular pathogenesis of acrylamide at the low level of 
dietary uptake is not understood. The present thesis is concerned with the question of 
whether transcriptional responses may amplify the known genotoxicity of acrylamide. 
Therefore, we used high-density DNA microarrays and PCR validations to assess 
genome-wide messenger profiles induced in human cells by acrylamide and glycidamide, 
its more reactive metabolite. The expression changes are characterized by the up-
regulation of cytoprotective factors including the glutathione system, carbonyl reductases 
and various antioxidants. Low-dose experiments indicate that epoxide hydrolase 1 
represents the most sensitive biomarker for the internal glycidamide exposure. At higher 
concentrations, glycidamide induces markers of tumor progression such as steroid 
hormone activators, regulators of nuclear factor-!B, growth stimulators and apoptosis 
inhibitors. Concomitantly, growth suppressors and cell adhesion molecules are 
suppressed. The main implication of these findings for risk assessment is that 
transcriptional signatures associated with tumor cell progression may be expected only at 
higher doses that exceed the range of ordinary dietary exposure. 
 5
2. INTRODUCTION 
              
 
2.1.  The HEATOX Project 
 
HEATOX (for HEAT-induced food TOXicants) is a 40-months European research 
project focused on the problem of food contaminants that are generated by heat 
processing. The project started on November 1st, 2003, and ended in February 2007. The 
main objectives were to assess possible health hazards and the magnitude of risks that 
may be associated with the uptake of hazardous substances arising in heat-treated food, 
and to find mitigation strategies to minimize the formation of such-heat induced 
compounds. The experimental work focused mainly on the new discovery that 
acrylamide, a genotoxic and potentially carcinogenic chemical, is formed in common 
carbohydrate-rich foods. The HEATOX project also coordinated the international 
collaboration of research activities in this area and involved all relevant key players 
including the scientific community, industry representatives, European commission 
services and consumer organizations. One of the key gaps of knowledge identified at the 
outset of the project was the lack of information on expression profiles induced by 
acrylamide. As a consequence, in the frame of this European cooperation, I assessed the 
transcriptional effects of acrylamide and its reactive metabolite glycidamide in human 
cells. This approach led to the identification of an alternative biomarker of exposure that 
is based on an active cellular response to stimulation by these chemicals. 
 
2.2.  Acrylamide and its formation in food 
 
Acrylamide is a high-production vinyl compound whose polymeric form is frequently 
used in the construction and oil industry, in the manufacture of paper and textiles, as a 
flocculant in the treatment of municipal waste water, and in cosmetic products (Friedman 
2003). A wave of worldwide public concern has been caused by the finding that the same 
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compound is generated in many common foods during cooking at high temperatures 
(Svensson et al. 2003). For example, acrylamide reaches parts per million concentrations 
in French fries, potato and tortilla chips, bread crust, various baked goods, breakfast 
cereals and coffee. 
 It was soon recognized that acrylamide is formed during the Maillard browning 
reaction from a heat-induced reaction between the amino acid asparagine and the 
carbonyl group of glucose (Mottram et al. 2002; Stadler et al. 2002). The Maillard 
browning is a non-enzymatic reaction, firstly described by Louis Maillard in 1912. It is 
characterized by the condensation of an amino group with a reducing sugar moiety when 
temperatures of more than 120°C are applied at conditions that reduce the local water 
content. The Maillard reaction is responsible for the typical taste, appearance and texture 
of the affected food items. Thus, most of the effects of this reaction, such as the 
introduction of caramel aromas and the golden brown color, are desirable. Unwanted 
effects of the Maillard reaction include the excessive food darkening, the off-flavor 
development and the generation of acrylamide. 
 
2.3. Glycidamide and detoxification processes 
 
A large fraction of the ingested acrylamide is converted to glycidamide by a member of 
the cytochrome P-450 superfamily, i.e., by cytochrome P-450 2E1 (CYP2E1) 
monooxygenase (Fig. 1). Glycidamide is an epoxide derivative that is substantially more 
reactive towards cellular macromolecules than acrylamide itself (Sumner et al. 1999). 
Unlike acrylamide, glycidamide has been found to yield positive results in the Ames test 
performed with Salmonella strains, implying that it displays a mutagenic activity 
(Hashimoto and Tanii 1985). In mammalian and human cells, glycidamide generates 
DNA strand breaks and induced the formation of different kinds of base adducts 
(Gamboa da Costa et al. 2003; Besaratinia and Pfeiffer 2003; Doerge et al. 2005), and 
these hazardous DNA lesions may be responsible for the mutagenic properties of 
glycidamide (Besaratinia and Pfeiffer 2004). When tested with short-term rodent studies, 
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glycidamide generates micronuclei in white blood cells, thus confirming that this 
compound displays potentially deleterious DNA-damaging effects (Paulsson et al. 2003; 
Baum et al. 2005; Puppel et al. 2005; Manjanatha et al. 2006). 
 
Figure 1.  Molecular structure of acrylamide and  glycidamide. Acrylamide is converted 
into glycidamide by cytochrome P-450 2E1 (CYP2E1). 
 
 Both acrylamide and glycidamide are rapidly detoxified by the action of glutathione-
S-transferase, which catalyzes the conjugation with glutathione (GSH). Subsequently, the 
resulting GSH conjugates are converted to mercapturic acid metabolites that are excreted 
in the urine. In addition, glycidamide is additionally inactivated by cleavage of the 
epoxide ring through the action of epoxide hydrolases (Odlund et al. 1994; Tong et al. 
2004).  
 
2.4. Carcinogenesis 
 
The long-term carcinogenicity studies in mice and rats demonstrated tumor induction by 
acrylamide at daily doses of 1 mg/kg body weight or higher (Friedman et al. 1995). This 
apparent threshold for tumor induction in rodents exceeds the ordinary dietary exposure 
of humans by several orders of magnitude. In fact, the average dietary intake of 
acrylamide in Western populations has been estimated to be in the range of !0.5 µg/kg 
body weight/day (Konings et al. 2003; Svensson et al. 2003; Dybing et al. 2005), 
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although children may be more highly exposed. Occupational exposures have been 
estimated in the daily range of 1 µg/kg body weight, whereas cigarette smoking leads to a 
considerably higher acrylamide intake of !3 µg/kg/day (Bergmark 1997). Based on the 
rodent studies, conventional low-dose extrapolations have been made for the incidence of 
human cancer associated with the ingestion of acrylamide contained in foods or 
beverages. Different quantitative estimates of lifetime cancer risks in human population 
range from 1 per 10’000 to 4.4 per 1’000 exposed individuals (reviewed by Dybing and 
Sanner 2003). On the other hand, exposure to acrylamide could not be linked to increased 
cancer mortality in any epidemiologic study (Marsh et al. 1999; Mucci et al. 2003; Rice 
2005; Pelucchi et al. 2006). Therefore, it remains difficult to establish the full extent of 
health risks resulting from the wide appearance of this food carcinogen (Erdreich and 
Friedman 2004).  
 
2.5. Biomarkers 
 
Because of their short half-lives, the detection of acrylamide or glycidamide in the blood 
or tissue of exposed people has remained elusive. However, hemoglobin adducts in 
blood, mercapturic acid metabolites in the urine or DNA adducts in target tissues have 
been proposed as indirect biomarkers to assess the internal exposure to acrylamide and its 
genotoxic metabolite glycidamide (Calleman et al. 1994; Bergmark 1997; Manière et al. 
2005; Fuhr et al. 2006). This approach has been useful for example to estimate the level 
of glycidamide that arises transiently in human blood after the consumption of 
acrylamide-containing food (unpublished results from the HEATOX consortium). On the 
other hand, it is not clear what level of hemoglobin adducts, urine metabolites, DNA 
adducts or other kinds of molecular damage could be tolerated without exceeding an 
acceptable level of cancer risk. As a consequence, we have performed a large-scale 
transcriptomic analysis, using high-density DNA microarrays, to identify differentially 
expressed genes that may be used as a true biomarker of hazardous effects in exposed 
tissues. 
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2.6. Basic Principle 
 
Traditional approaches in toxicology involve the use of high doses of the chemicals under 
scrutiny, thus inducing some kind of severe damage to organs, tissues, cells, organelles or 
macromolecules. Alternatively, a large number of cellular bioassays have been developed 
to assess molecular responses to potentially toxic compounds. In most cases, the tested 
chemical is able to stimulate a particular receptor, leading to activation of signaling 
cascades that eventually induce an active cellular response such as apoptosis, gene 
induction, protein modification or other biochemical reactions. 
Traditional bioassays are normally focused on the measurement of a single cellular 
response. However, a new approach in toxicology takes advantage of newly developed 
large-scale analyses such as transcriptomics or proteomics. Using these large-scale 
strategies it has become possible to monitor multiple endpoints simultaneously, thus 
obtaining molecular profiles or “fingerprints” that are characteristic for the action of 
particular groups of toxic chemicals (Fig. 2). Transcriptomics is based on the 
simultaneous quantitative measurement of a large number of messenger RNA transcripts 
coding for specific cellular proteins.  
 
Figure 2: Principle of multi-endpoint bioassays enabling expression profiles monitoring 
at mRNA levels. 
 10
 
 
 A standard human breast tumor cell line (MCF7) was selected as the primary target of 
these transcriptomic experiments because the lifetime rodent studies yielded mammary 
gland adenomas and adenocarcinomas in females (Friedman et al. 1995), and because the 
appearance of acrylamide in mammary glands has been demonstrated after ingestion of 
contaminated food (Sorgel et al. 2002). The selected MCF7 cells have been shown to 
display intact p53-dependent reactions, including cell cycle arrest and apoptosis, in 
response to DNA damaging agents (Calcabrini et al. 2006; Hernandez-Vargas et al. 2006; 
Ray et al. 2006). Additionally, the human colonic cell line CaCo-2 has been tested as a 
system that mimics the absorptive barrier of an intestinal epithelium (Meunier et al. 
1995).  
 
2.7. Aims 
 
The goal of the present study was to use the most advanced transcriptomic platform to 
monitor, at the transcriptional level, the expression changes induced in human cells by 
exposure to acrylamide or glycidamide. The purpose of these studies was to test whether 
the genomic reprogramming elicited by acrylamide or glycidamide may potentiate or, 
alternatively, counteract the known genotoxic effects of these compounds. 
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3.   MATERIALS AND METHODS 
               
 
3.1.  Chemicals 
 
Glycidamide was purchased from Toronto Research Chemicals (Canada) and acrylamide 
was from Fluka (Buchs, Switzerland). Both chemicals were dissolved in distilled water. 
All other reagents used were of the highest purity that is commercially available. 
 
3.2. Cell culture and treatments 
 
All cell culture media were from Gibco. The MCF7 cell line subtype BUS (provided by 
A. M. Soto and C. Sonnenschein, Tufts University, Boston, USA) was grown in 
Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine 
serum (FBS). The antibiotics used were 0.1 U/ml penicillin and 0.1 µg/ml streptomycin. 
CaCo-2 cells (obtained from A. Pospischil, Institute of Veterinary Pathology, University 
of Zürich, Switzerland) were maintained in a 1:1 mixture of DMEM and Ham’s F12 
complemented by 10% FBS, 1% non-essential amino acids and antibiotics. Both cell 
lines were tested for the absence of Mycoplasma infection and cultured to 90% 
confluence at 37°C in xenoestrogen-free plastic (Corning Inc., Grand Island, USA) under 
humidified air containing 5% CO2. 
 Before each exposure to the chemicals, the growth medium was replaced by phenol 
red-free DMEM/F12 and cells were cultured for 48 h in the presence of 5% 
charcoal/dextran-stripped FBS (lacking estrogens or other growth factors that trigger the 
cell cycle), followed by the addition of acrylamide or glycidamide at the indicated 
concentrations. Glycidamide has been shown to be stable under these conditions (Silvari 
et al. 2005). 
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3.3. Cytotoxicity and caspase assays 
 
A commercial kit was used to measure intracellular ATP levels. Briefly, MCF7 cells 
were grown in multi-well plates and exposed to the indicated concentrations of 
acrylamide or glycidamide. After 24 h, the CellTiter-Glo reagent (Promega) was added 
and the luminescent signal was recorded in a microplate reader following the 
manufacturer’s instruction. The CellTiter 96 and CytoTox 96 assays (Promega) were 
used to monitor the metabolic activity and the release of lactate dehydrogenase. The 
luminescent Caspase-Glo assay (Promega) was used to determine the activity of caspases 
3 and 7.  
 
3.4. Gene expression analysis 
 
After 24-h incubations with acrylamide or glycidamide, the cells were collected by 
trypsinization and total RNA was extracted with the RNeasy mini kit (Qiagen). The 
quality of RNA was determined on the Agilent Lab-on-a-chip Bioanalyzer 2000. Samples 
with a total area under the 28S and 18S bands of less than 65% of total RNA, as well as a 
28S/18S ratio of less than 1.5, were considered to be degraded and therefore excluded 
from microarray analyses. The GeneChip Expression and IVT Labelling kits 
(Affymetrix) were used for the synthesis of complementary DNA and complementary 
RNA, respectively. The biotin-labeled RNA was fragmented and hybridized on Human 
Genome U122 plus 2.0 microarrays (Affymetrix) following the manufacturer’s 
instructions. 
 After hybridization (16 h), the microarrays were processed by automated washing on 
the Affymetrix Fluidics Station 400. Staining of the hybridized probes was performed 
with fluorescent streptavidin-phycoerythrin  conjugates (1 mg/ml; Molecular Probes). 
The subsequent scanning of DNA microarrays was carried out on an Affymetrix laser 
instrument. The data sets were normalized and analyzed using the GeneSpring 7.2 
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software (Silicon Genetics). The gene ontology database (www.geneontology.org) was 
consulted for the molecular function of each transcript. 
 
3.5. Real-time quantitative RT-PCR 
 
TaqMan gene expression assays containing pre-designed primers and probes for the 
selected transcripts and TaqMan universal PCR master mix were obtained from Applied 
Biosystems. Briefly, 100 ng of complementary DNA were mixed with 100 nM of 
forward and reverse primers in a final volume of 25 µl. The reactions were performed in 
an ABI PRISM 7700 Sequence Detection System (Applied Biosystems) in 45 cycles 
(95°C for 15 sec, 60°C for 1 min) after an initial 10-min incubation at 95°C. The fold 
change in the expression of each gene was calculated using the 2-!!CT method (Livak and 
Schmittgen 2001), with the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
transcript as an endogenous control. 
 
3.6. Glutathione assay 
 
MCF7 or CaCo-2 cells were grown in 6-well plates until a confluence of 90%. After 
treatment with the indicated glycidamide concentrations (in 3 ml medium), 5x105 cells 
were washed with phosphate-buffered saline, deproteinated with 10 mM HCl, and lysed 
by freezing and thawing. The pH was neutralized with 5% (w/v) 5-sulfosalicylic acid 
dihydrate (Fluka). After centrifugation, reduced GSH in the supernatant was measured 
with the colorimetric QuantiChrom Glutathione Assay kit (BioAssay Systems, Hayward, 
USA) following the manufacturer’s instructions. 
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3.7.  NF-!B reporter assay 
 
MCF7 cells (70% confluent) were co-transfected (jetPEI reagent, PolyPlus-Transfection, 
Illkirch, France) with the reporter construct pBII-Luc, carrying the firefly luciferase gene 
under control of NF-!B binding sites (Hassa et al. 2001), and the vector pRL-TK 
(Promega), which drives the constitutive expression of the Renilla luciferase. A pBII-Luc 
derivative lacking NF-!B binding sites was used to test the assay specificity. After 
transfection, cells were allowed to recover for 2 h before exposure to the indicated 
concentrations of glycidamide. Following varying incubation times, firefly and Renilla 
luciferase expression were determined in cell lysates using the Dual Luciferase system 
(Promega). Induction of the reporter gene was then calculated from the ratio of activity of 
the two enzymes. 
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4.  RESULTS 
               
 
4.1. Glycidamide toxicity 
 
The dose range to be tested in the DNA microarray experiments has been determined 
using standard viability assays. Human MCF7 mammary tumor cells were exposed for 24 
h to increasing concentrations of glycidamide or the parent compound acrylamide. Cell 
viability was tested by measuring the intracellular ATP concentration, which is used as an 
indicator of overall metabolic activity. The resulting dose response demonstrated that 
neither glycidamide nor acrylamide exerted cytotoxic effects at concentrations of up to 1 
mM (Fig. 3). A significant reduction of ATP levels was observed only following the 10-
mM glycidamide treatment. 
  
 
 
Figure 3. Cytotoxicity of acrylamide and glycidamide. Confluent MCF7 cell cultures 
were treated with increasing concentrations of each chemical for 24 h. Subsequently, 
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their metabolic activity was determined by measuring intracellular ATP pools and the 
results are expressed as the percentage of the ATP concentration found in untreated 
controls (mean of five independent determinations). Error bars = 95% confidence 
intervals. The asterisk indicates a statistically significant difference between cells treated 
with acrylamide or glycidamide at a 1-mM concentration (P < 0.05, Mann-Whitney U 
test). 
 
 
Comparable results, i.e., no cytotoxicity at concentrations of up to 1 mM, were obtained 
when the metabolic activity was assessed with the tetrazolium reagent (MTT assay) or 
when cell lysis was measured by the release of lactate dehydrogenase into the cell culture 
supernatant (data not shown). In the same concentration range of up to 1 mM, there was 
no activation of caspases 3 and 7 following 24-h exposures to glycidamide and 
acrylamide (data not shown), suggesting that both compounds fail to induce an apoptotic 
response. These toxicity assays performed over short 24-h periods cannot exclude that 
cell survival may be affected after longer incubation times. 
 
4.2. Expression profiling 
 
High-density oligonucleotide microarray experiments were performed to determine 
global changes of gene expression in MCF7 cells. Each transcriptome was assessed in 
three independent experiments using separate cell cultures and RNA preparations. 
Following 24-h glycidamide or acrylamide treatments, the messenger RNA was analyzed 
on Affymetrix U122 plus 2.0 microarrays covering the sequences of ~47,000 human 
transcripts. Approximately 35% of all examined gene products were called to be present 
by the GeneChip Operating 3.0 software. 
 Fig. 4A compares the profiles of two independent experiments conducted with 
untreated MCF7 cells, i.e., in the absence of glycidamide or acrylamide stimulation. In 
this case, the data points accumulate along the diagonal axis of the scatter plot, thus 
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illustrating that repeated microarray determinations yielded nearly identical results. These 
baseline values were then plotted against the transcriptional profiles obtained by exposing 
MCF7 cells to 1-mM concentrations of the test compounds. In the comparison between a 
representative control sample and the 1-mM glycidamide treatment, the cloud of data 
became much wider indicating that a large number of genes are either over- or 
underexpressed upon glycidamide exposure (Fig. 4B). In response to acrylamide, 
however, the expression values were closer to the baseline control (Fig. 4C), indicating 
that the parent compound itself induces less prominent changes of gene expression. In 
view of the more conspicuous transcriptional effects elicited by glycidamide, only the 
genomic response to this oxidative metabolite was further investigated at lower doses. 
 
 
Figure 4. Overall expression changes. Each scatter plot shows the normalized data from 
individual hybridizations on Affymetrix high-density DNA microarrays. The messenger 
RNA levels are expressed in arbitrary units. (A) Comparison between the transcriptome 
of two independent samples of untreated MCF7 cells. (B) Comparison between an 
untreated control and MCF7 cells exposed to 1 mM glycidamide. (C) Comparison 
between the same untreated control and MCF7 cells treated with 1 mM acrylamide. 
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4.3. Multivariate analysis of transcriptomes 
 
The GeneSpring 7.2 software was employed to integrate the hybridization intensities of 
triplicate experiments and to perform data analysis. The principal component analysis 
(PCA) constitutes a linear dimensionality reduction technique that is commonly applied 
to classify complex transcriptional patterns (Van der Werf et al. 2006). The resulting 
output can be visualized in two-dimensional plots, where each point represents the entire 
transcriptome of a single sample. Transcriptomes that cluster together are overall very 
similar, whereas transcriptional patterns that differ from each other are located further 
apart. 
 Fig. 5 demonstrates that all expression profiles obtained by exposing MCF7 cells to 
glycidamide, at concentrations between 1 µM and 1 mM, are clearly separated from the 
untreated controls, implying that the changes due to technical variation are less important 
than the gene regulation occurring in response to different concentrations of the test 
compound. Individual experiments from each treatment group cluster closely together 
but, with increasing glycidamide concentrations, we observed a gradual shift along the X-
axis, which represents the component that accounts for the highest proportion (81.1%) of 
the total variance. 
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Figure 5. PCA plot of the transcription profiles in MCF7 cells exposed to increasing 
concentrations of glycidamide. Each treatment group consists of three independent 
experiments. 
 
 
This principal component shows that the gene expression program of MCF7 cells is 
altered by glycidamide exposure in a dose-dependent manner. Interestingly, a minor 
component (PC2 on the Y-axis) accounts for only 5.9% of the total variance, although it 
clearly separates the 1-µM treatments from all other experiments. 
 
4.4. Univariate transcriptome analysis 
 
The fold differences for each detectable transcript were determined from the comparison 
between glycidamide-treated MCF7 cells and the reference values from unexposed 
controls. These differential expression data were filtered using, as thresholds, a fold 
change of > 3.0 and a statistical significance of P < 0.05 (two-sided ANOVA) in at least 
one of the treatment groups. The false discovery rate according to Benjamini and 
Hochberg (Benjamini and Hochberg, 1995) was < 0.1. This analysis yielded > 100 
glycidamide-regulated transcripts that encode protein products whose known or inferred 
biological functions fall into three categories.  
 A major functional cluster comprises detoxification processes involving two routes of 
glycidamide inactivation, i.e., GSH conjugation and opening of the epoxide ring by 
epoxide hydrolases (Table 1A). In particular, the GSH system was modulated by 
overexpression of GCLM, a regulatory subunit that stimulates the cysteine ligase in 
catalyzing the rate-limiting step of GSH biosynthesis (Lee et al. 2006). The capacity of 
this pathway was further enhanced by the up-regulation of a membrane carrier 
(SLC7A11) that mediates the cellular uptake of cystine moieties required for GSH 
production (Huang et al. 2005). 
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Table 1A. Regulation of transcripts coding for factors involved in detoxification (fold 
changes of expression relative to untreated controls). All concentrations tested in 
triplicates. 
Name Description Glycidamide (mM) 
  0.001   0.01      0.1 1 
SLC7A11 Solute carrier family 7, member A11 1.4 1.5 1.6 37.3 
AKR1B10 Aldo-keto reductase family 1, member B10 -2.4 -1.5 1.8 32.4 
GPX2 Glutathione peroxidase 2 1.0 1.1 2.4 20.0 
LTB4DH Leukotriene B4 12-hydroxydehydrogenase -1.4 -2.0 1.3 14.5 
CYP4F11 Cytochrome P450, family 4, subfamily F, polypeptide 11 1.0 1.1 1.2 13.5 
AKR1C3 Aldo-keto reductase family 1, member C3 1.2 1.1 1.2 10.6 
ME1 Malic enzyme 1 -1.3 -1.5 1.9 7.8 
AKR1C1 Aldo-keto reductase family 1, member C1 -1.5 -1.4 4.1 7.5 
DHRS2 Dehydrogenase/reductase (SDR family) member 2 1.1 1.0 1.0 7.5 
AKR1C2 Aldo-keto reductase family 1, member C2 -1.2 1.2 1.8 6.2 
GCLM Glutamate-cysteine ligase, modifier subunit -1.3 -1.3 1.4 6.2 
GPX3 Glutathione peroxidase 3 1.5 -1.2 1.0 6.0 
EPHX1 Epoxide hydrolase 1 1.2 1.8 1.2 5.2 
MGST1 Microsomal glutathione S-transferase 1 1.2 1.2 1.3 4.9 
CBR1 Carbonyl reductase 1 1.5 1.0 1.6 4.4 
CBR3 Carbonyl reductase 3 1.3 -1.1 1.0 4.2 
G6PD Glucose-6-phosphate dehydrogenase 1.2 1.4 1.0 4.2 
SULT1A3,4 Sulfotransferase family 1A, member 3 and 4 1.7 1.2 1.1 3.4 
ESD Esterase D/formylglutathione hydrolase 1.4 1.1 1.4 3.2 
SULT1A1 Sulfotransferase family 1A, member 1 1.7 1.1 1.1 3.1 
CYP4B1 Cytochrome P450, family 4, subfamily B, polypeptide 1 1.1 -1.5 -1.6 -19.0 
CYP1B1 Cytochrome P450, family 1, subfamily B, polypeptide 1 -2.0 -1.7 -1.4 -18.5 
ALDH3B2 Aldehyde dehydrogenase 3 family, member B2 -1.2 -1.1 -1.4 -15.5 
ALDH4A1 Aldehyde dehydrogenase 4 family, member A1 -1.2 -1.3 -1.5 -4.6 
CYP1A1 Cytochrome P450, family 1, subfamily A, polypeptide 1 -1.7 -4.5 -7.0 -4.0 
IDH2 Isocitrate dehydrogenase, mitochondrial 1.2 -1.1 -1.2 -3.5 
CYP2J2 Cytochrome P450, family 2, subfamily J, polypeptide 2 1.6 1.1 -1.1 -3.2 
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As shown in Table 1A, glycidamide exposure led to transcriptional induction of the 
following other members of the GSH system: a transferase that catalyzes the conjugation 
of toxicants to the GSH moiety (MGST1), two distinct GSH peroxidases (GPX2 and 
GPX3), and metabolic enzymes (ME1, G6PD) that contribute to NADPH synthesis, 
thereby promoting the turnover of oxidized GSSG. Further effects of glycidamide 
treatment include the overexpression of reductases (DHRS2, AKR1B10, AKR1C1, 
AKR1C2, AKR1C3, LTB4DH, CBR1, CBR3 and ESD) that protect the organism from 
toxic carbonyl compounds (Dick et al. 2001; Covarrubias et al. 2006). Finally, we 
observed that one representative of the cytochrome P450 superfamily (CYP4F11) was 
overexpressed, whereas CYP1A1, CYP1B1, CYP2J2 and CYP4B1 were transcriptionally 
repressed in glycidamide-treated cells. A comparison with the 1-mM acrylamide 
treatment (Fig. 4C) showed that many of these glycidamide-responsive transcripts were 
also regulated by acrylamide, but with amplitudes of induction or repression that were at 
least four times lower than those observed with an equivalent concentration of 
glycidamide (data not shown). 
 The second functional cluster involves a dual response to oxidative stress (Table 1B). 
One part of this reaction is the induction of intracellular antioxidants such as the 
thioredoxin/thioredoxin reductase system, sulfiredoxin (SRXN1) and peroxiredoxins 
(PRDX3 and PRDX6). Lipoic acid synthase (LIAS) contributes to the same 
cytoprotective mechanism as this enzyme catalyzes the synthesis of lipoic acid, a potent 
natural antioxidant (Yi and Maeda 2005). In addition, cells react to oxidative stress by 
removing damaged protein aggregates. This response is evidenced by the induction of a 
ubiquitin-dependent protease (USP40) as well as by the overexpression of components of 
the autophagic system (APG3, CLTC and SQSTM1). Another transcript overexpressed in 
glycidamide-treated cells codes for MAFG, which is one of the MAF proteins that are 
essential for the induction of antioxidant factors (Katsuoka et al. 2005). Finally, we 
observed that glycidamide treatment stimulates the expression of EME1, a key DNA 
repair endonuclease (McPherson et al. 2004). 
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Table 1B. Regulation of factors involved in the oxidative stress response (fold changes of 
expression relative to untreated controls). All concentrations tested in triplicates. 
Name Description Glycidamide (mM) 
  0.001  0.01      0.1 1 
MTABC3 Mammalian mitochondrial ABP protein 3 1.1 1.0 1.4 16.5 
USP40 Ubiquitin-specific protease 40 1.2 1.4 1.6 6.1 
TXNRD1 Thioredoxin reductase 1 -2.9 -2.9 1.5 6.0 
APG3 Autophagy Apg3p/Aut1p-like -1.2 -1.2 1.1 6.0 
HMOX Heme oxygenase 1 1.0 1.0 1.2 5.7 
CLTC Clathrin, heavy polipeptide 1.5 1.0 1.4 5.1 
SRXN1 Sulfiredoxin 1 -1.3 -1.5 1.3 5.0 
NQO1 NAD(P)H dehydrogenase, quinone 1 -1.1 -1.5 1.7 4.5 
FTH1 Ferritin, heavy polypeptide 1 -1.6 -1.1 1.2 4.1 
PRDX6 Peroxiredoxin 6 1.2 -1.6 -1.3 3.9 
MAFG Sushi domain containing 4 -1.1 -1.3 1.1 3.8 
EME1 Essential meiotic endonuclease 1 -1.2 2.1 2.8 3.7 
TXN Thioredoxin 1.7 1.4 2.0 3.6 
LIAS Lipoic acid synthetase 1.6 -1.2 1.2 3.6 
SQSTM1 Sequestosome 1 -1.6 -1.3 1.2 3.4 
FECH Ferrochetalase 1.2 1.1 1.2 3.4 
PRDX3 Peroxiredoxin 3 1.4 1.1 1.2 3.3 
SELENBP1 Selenium binding protein 1 1.2 1.0 -1.3 -7.5 
SEPP1 Selenoprotein P, plasma, 1 -1.1 -1.1 -1.4 -8.3 
 
 
 
The third functional cluster is related to cancer progression (Table 1C). Glycidamide 
exposure of MCF7 cells resulted in the transcriptional regulation of many genes linked to 
malignancy or tissue invasion, including the growth factors OPG, ARC, HIP, KITLG, 
METAP2, and the insulin-like growth factor (IGF) receptor IGFR2 (see discussion). The 
response to glycidamide is further characterized by the down-regulation of transcripts 
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coding for cell adhesion molecules, including ITGB6, CDH12, CTNND2, ITGA6, 
SHANK2 and ANKRD34 (Table 1C). This same endpoint is favored by the induction of 
TRPM7, which suppresses cell adhesion (Su et al. 2006), and the transcriptional down-
regulation of tissue inhibitors of metalloproteinases (TIMP3, TIMP2). The growth-
inhibitory factors ING3, CASP7 and GADD45B were underexpressed. In addition, a 
Medline search showed that many other down-regulated transcripts (SASH1, PGM2L1, 
PACE4, CAV1, PRLR, DOCK8, CA12, CRABP2, WWOX, PTPN13 and ST7; bottom 
of Table 1C) have previously been associated with the suppression of cell transformation 
and tumor progression. 
 
 
Table 1C. Regulation of transcripts linked to cancer progression (fold changes of 
expression relative to untreated controls). All concentrations tested in triplicates. 
Name Description Glycidamide (mM) 
  0.001  0.01     0.1 1 
TD2L Tumor differentially expressed 2 like 1.3 1.3 1.1 11.9 
RANK Receptor activator of NF-!B 1.7 -1.9 1.2 8.7 
HNLF Putative NF-!B activating protein HNLF 1.6 1.4 1.6 7.8 
TRPM7 Transient receptor potential cation channel 1.6 2.1 1.6 5.2 
OPG Osteoprotegerin  -1.7 -1.6 1.1 5.2 
COMMD10 COMM domain containing 10, a NF-!B inhibitor 1.0 -1.2 1.0 4.7 
CAPN7 Calpain 7 1.1 2.0 1.5 4.1 
HIP14 Huntingtin interacting protein 14 1.6 1.5 1.4 3.9 
CCNI Cyclin I 1.1 1.1 1.0 3.6 
TNFSF9 Tumor necrosis factor (ligand) superfamily, member 9 1.0 -1.1 1.3 3.6 
MAPK12 Mitogen-activated protein kinase 12 1.0 1.0 1.0 3.3 
TNFRSF25 Tumor necrosis factor receptor superfamily, member 25 1.0 1.0 1.0 3.1 
IGF2R Insulin-like growth factor 2 receptor 1.3 1.3 1.4 3.1 
METAP2 Methionyl aminopeptidase 2 1.3 1.2 1.1 3.1 
ARC Apoptosis repressor with caspase-resistant domain  1.7 1.1 1.3 3.0 
KITLG KIT ligand -1.1 1.1 1.2 3.0 
ITGB6 Integrin, beta 6 1.2 -1.8 -1.6 -63.6 
ANXA1 Annexin A1 1.1 1.2 -1.6 -38.3 
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IL1R1 Interleukin 1 receptor type 1 -1.1 -1.8 -1.8 -24.3 
WISP2 WNT1 inducible signalling pathway protein 2 1.1 -2.3 -1.9 -22.0 
IGFBP4 Insulin-like growth factor binding protein 4 3.9 1.2 -2.0 -21.9 
TM4SF1 Transmembrane  superfamily member 1 -1.2 -1.4 -1.9 -18.4 
HS6ST2 Heparan sulfate 6-O-sulfotransferase 2 -1.2 -1.8 -3.2 -18.1 
IFITM1 Interferon-induced transmembrane protein 1 -1.1 -1.2 -2.4 -17.3 
SASH1 SAM and SH3 domain containing 1 -1.7 -1.1 -1.1 -17.0 
TIMP3 Tissue inhibitor of metalloproteinase 3 -1.5 1.2 -1.6 -14.6 
IGFBP5 Insulin-like growth factor binding protein 5 1.5 -1.2 -1.4 -13.0 
PGM2L1 Phosphoglucomutase 2-like 1 -1.6 -1.7 -1.1 -10.9 
SIDT1 SID1 transmembrane family member 1 -1.1 -1.3 -1.4 -10.7 
PACE4 Paired basic amino acid cleaving system 4 -1.4 -1.5 -1.1 -10.1 
CAV1 Caveolin 1 1.7 -1.6 -1.4 -9.5 
CDH12 Cadherin 12, type 2 (N-cadherin 2) -1.1 -1.0 -1.1 -8.1 
PRLR Prolactin receptor 1.3 -1.1 -1.4 -7.7 
SELENBP1 Selenium binding protein 1 1.2 1.0 -1.3 -7.5 
DOCK8 Dedicator of cytokinesis 8 -1.1 -1.7 -1.1 -7.4 
CAPN2 Calpain 2 lage subunit -1.3 -3.7 -3.7 -6.6 
SIAT4A Sialyltransferase 4A  -1.7 -1.9 -1.2 -6.4 
FHOD3 Formin homology 2 domain containing 3 -1.2 -6.2 -4.9 -6.2 
CA12 Carboanhydrase XII 1.0 -1.5 -1.1 -6.0 
CRABP2 Cellular retinoic acid binding protein 2 1.3 1.3 -1.4 -6.0 
ING3 Inhibitor of growth family, member 3 -1.1 -1.4 1.2 -5.9 
CTNND2 Catenin (Cadherin associated protein), delta 2 -1.5 -2.0 -1.2 -5.5 
CAV2 Caveolin 2 1.2 -1.6 -1.4 -5.5 
WWOX WW domain containing oxidoreductase 1.1 1.0 1.0 -5.3 
PTPN13 Protein tyrosine phosphatase, non-receptor type 13 1.0 -1.4 -1.2 -5.0 
SHANK2 SH3 and multiple ankyrin repeat domains 2 -1.4 -1.6 -1.1 -4.6 
CAPN13 Calpain 13 1.0 1.0 -1.3 -4.0 
TMEM46 Transmembrane protein 46 -1.2 -1.6 -1.9 -4.0 
TMPRSS2 Transmembrane protease serine 2 -1.1 -1.7 -1.3 -4.0 
IGFBP2 Insulin-like growth factor binding protein 2 1.7 -1.2 -1.6 -3.9 
ITGA6 Integrin, alpha 6 -1.3 -3.4 -4.0 -3.8 
CASP7 Caspase 7, apoptosis-related cysteine protease -1.1 -1.2 -1.1 -3.8 
TIMP2 Tissue inhibitor of metalloproteinase 2 -1.2 -3.9 -2.5 -3.8 
ANKRD34 Ankyrin repeat domain 34 1.3 1.1 1.1 -3.7 
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ST7 Suppression of tumorigenicity 7 -1.7 -2.3 -2.4 -3.4 
TRAF5 TNF receptor-associated factor 5 -1.1 -1.2 1.0 -3.4 
GADD45B Growth arrest and DNA-damage-inducible, beta 1.3 -1.1 -1.2 -3.3 
MMP16 Matrix metalloproteinase 16 (membrane-inserted) 1.2 1.3 -1.1 -3.1 
 
 
 
4.5. Data verification by RT-PCR analysis 
 
DNA microarry hybridization is a multiple-comparison procedure with an inherent false 
discovery rate (Benjamini and Hochberg 1995). Therefore, it is necessary to validate the 
microarray results with a quantitative method targeted to single endpoints. First, real-time 
reverse transcriptase (RT)-PCR determinations were carried out on 16 transcripts using 
the RNA samples obtained from the previous high-dose experiments with 100 µM and 1 
mM glycidamide. After normalization with the GAPDH (glyceraldehyde-3-phosphate 
dehydrogenase) housekeeping control, expression values were determined as the ratio of 
messenger level between glycidamide-exposed and untreated cells. A direct comparison 
of the microarray hybridization results with the respective RT-PCR values revealed a 
high degree of correlation for the transcripts that were regulated by the glycidamide 
stimulus in a significant manner. The only exception among the 16 tested mRNAs was 
the BRCA2 transcript, for which a more moderate induction was found by RT-PCR than 
in the microarray hybridizations (data not shown). 
 The same transcripts (except the BRCA2 messenger) were further analyzed to verify 
the reproducibility of these findings. For that purpose, the treatment of MCF7 cells was 
repeated with a new series of triplicate experiments, thus generating an independent set of 
samples for RT-PCR analysis. After normalization against the GAPDH housekeeping 
control, the expression values were again transformed to ratios between glycidamide-
exposed and untreated cells. The results of Fig. 4A show that, as it was found by 
microarray hybridizations, some transcripts were consistently up-regulated following a 
treatment with only 1 µM glycidamide. Examples of this low-dose response are EPHX1 
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(an epoxide hydrolase) and SLC7A11. Additional experiments conducted with even 
lower toxicant levels showed that EPHX1 is significantly (P < 0.001) up-regulated by a 
factor of 1.6 + 0.05 following a 0.1-µM glycidamide treatment. Other transcripts (EME1, 
GCLM or AKR1C2) were down-regulated in the presence of 1 µM glycidamide, but up-
regulated at higher concentrations (see Tables 1A-C and Fig. 4A). On the other hand, the 
FHOD3 transcript (coding for a putative regulator of actin function; Katoh and Katoh 
2004) was down-regulated at all glycidamide concentrations of 1 µM or higher (Table 
2A).  
 
 
Table 2A. Quantification of the MCF7 microarray data by real-time RT-PCR. Analysis of 
15 representative transcripts 10 of which were found to be up-regulated after a 1-mM 
glycidamide exposure and 5 of which were found to be down-regulated by the 1-mM 
exposure to glycidamide in the previous microarray determinations. All results (fold 
changes relative to untreated controls) are shown as the mean values of three 
independent determinations. The standard deviations of the three fold change values are 
indicated in brackets.  Asterisks indicate values that are significantly different from the 
unexposed controls (P < 0.05, Mann-Whitney U test). 
Name Description Glycidamide (mM) 
  0.001 
(Stdev) 
 0.01 
(Stdev) 
    0.1 
(Stdev) 
1 
(Stdev) 
GPX2 Gutathione peroxidase 2 -1.02 
(0.004) 
1.11* 
(0.035) 
2.37* 
(0.176) 
81.19* 
(3.268) 
SLC7A11 Solute carrier family 7, member A11 1.43* 
(0.123) 
1.54* 
(0.035) 
2.14* 
(0.060) 
41.84* 
(1.174) 
AKR1C3 Aldo-keto reductase family 1, member C3 1.19 
(0.095) 
1.12* 
(0.047) 
1.93* 
(0.281) 
20.4* 
(1.555) 
AKR1C2 Aldo-keto reductase family 1, member C2 -1.25 
(0.328) 
1.23* 
(0.064) 
1.6 
(0.346) 
19.95* 
(3.447) 
EPHX1 Epoxide hydrolase 1 1.55* 
(0.040) 
1.5* 
(0.055) 
1.37 
(0.105) 
9.69* 
(1.845) 
GCLM Glutamate-cysteine ligase, modifier subunit -1.28 -1.29 1.18 8.55* 
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(0.031) (0.118) (0.125) (1.158) 
CYP4F11 Cytochrom P450, family 4, subfamily F, polypeptide 11 1.03 
(0.191) 
1.12 
(0.078) 
1 
(0.070) 
7.36* 
(0.144) 
RRM2 Ribonucleotide reductase M2 polypeptide 1.35 
(0.166) 
1.15* 
(0.012) 
1* 
(0.354) 
2.83* 
(0.359) 
TXN Thioredoxin 1.07 
(0.037) 
1 
(0.002) 
1.11 
(0.056) 
2.3* 
(0.171) 
EME1 Endomeiotic endonuclease 1 -1.17* 
(0.042) 
-1.01 
(0.122) 
1.24* 
(0.067) 
2.27* 
(0.229) 
FHOD3 Formin homology domain containing 3 -1.30* 
(0.044) 
-1.30 
(0.159) 
-1.89* 
(0.131) 
-66.67* 
(0.003) 
ITGB6 Integrin beta 6 1.17 
(0.036) 
1.42 
(0.163) 
-1.79* 
(0.035) 
-35.71* 
(0.002) 
CAPN13 Calpain 13 1 
(0.032) 
1 
(0.046) 
-1.30* 
(0.060) 
-30.30* 
(0.004) 
CDH12 Cadherin 12 -1.14* 
(0.046) 
1.20 
(0.136) 
-1.15 
(0.115) 
-12.94* 
(0.0003) 
ANXA1 Annexin A1 1.06 
(0.059) 
1.16 
(0.140) 
-2.27* 
(0.021) 
-12.82* 
(0.015) 
 
 
 
We next extended this RT-PCR analysis to the human colonic cell line CaCo-2, which 
has been shown to mimic the absorptive properties of a differentiated intestinal 
epithelium (Meunier et al. 1995). Interestingly, we found that CaCo-2 cells react to 
glycidamide with a transcriptional response that largely overlaps with that observed in 
MCF7 cells. Examples of this convergent regulation in the two different cell lines include 
the overexpression of SLC7A11, GCLM, CYP4F11, AKR1C3, and GPX2, and the 
common underexpression of ITGB6 and CAPN13 (Table 2B). ANXA1 was down-
regulated in MCF7 but up-regulated in CaCo-2 cells. Some other transcripts (AKR1C2, 
CDH12 and FHOD3) turned out to be absent in CaCo-2 cells.  
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Table 2B. Quantification by real-time RT-PCR (CaCo2). The 15 transcripts verified in 
MCF7 by Real-time PCR were tested in the CaCo2 cell line. 6 of them were found to be 
up-regulated after a 1-mM glycidamide exposure and 2 of them were found to be down-
regulated by the 1-mM exposure to glycidamide. All results (fold changes relative to 
untreated controls) are shown as the mean values of three independent determinations. 
The standard deviations of the three fold change values are indicated in brackets. . 
Asterisks indicate values that are significantly different from the unexposed controls (P < 
0.05, Mann-Whitney U test). 
Name Description Glycidamide (mM) 
  0.001 
(Stdev) 
 0.01 
(Stdev) 
    0.1 
(Stdev) 
1 
(Stdev) 
SLC7A11 Solute carrier family 7, member A11 -1.20 
(0.052) 
-1.03 
(0.024) 
1.78* 
(0.087) 
15.24* 
(0.597) 
GCLM Glutamate-cysteine ligase, modifier subunit -1.54* 
(0.012) 
-1.57 
(0.004) 
-1.11 
(0.927) 
10.56* 
(0.001) 
CYP4F11 Cytochrom P450, family 4, subfamily F, polypeptide 11 1.00 
(0.108) 
1.11* 
(0.035) 
-4.85* 
(0.065) 
7.38* 
(1.726) 
AKR1C3 Aldo-keto reductase family 1, member C3 1.04 
(0.104) 
1.05 
(0.032) 
1.573* 
(0.011) 
7.26* 
(0.313) 
ANXA1 Annexin A1 -1.96* 
(0.035) 
-1.79* 
(0.063) 
-1.63* 
(0.024) 
3.97* 
(0.176) 
GPX2 Glutathione peroxidase 2 -1.45* 
(0.057) 
-1.01 
(0.131) 
1.44* 
(0.088) 
3.46* 
(0.176) 
ITGB6 Integrin beta 6 -1.10* 
(0.023) 
-1.30* 
(0.073) 
-1.23* 
(0.025) 
-5.05* 
(0.021) 
CAPN13 Calpain 13 1.00 
(0.046) 
1.10 
(0.075) 
1.01 
(0.018) 
-3.56* 
(0.023) 
 
 
 
4.6. Changes of GSH status 
 
Considering that many factors involved in the GSH system are induced upon glycidamide 
treatment (Table 1A), we tested the consequence of glycidamide exposure on the 
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effective intracellular GSH level. Approximately 3 million cells (corresponding to a total 
intracellular volume of about 3 µl) were exposed to medium (3 ml) containing increasing 
concentrations of glycidamide or acrylamide. Interestingly, we found that the GSH pool 
of MCF7 cells was partially depleted after a 24-h incubation with 1 µM glycidamide (Fig. 
6A). At higher concentrations, the normal GSH concentration was gradually reconstituted 
and, after a 1-mM glycidamide exposure, the GSH pool of MCF7 cells reached a higher 
level than in the untreated controls. 
 Similarly, CaCo-2 cells respond to 1-µM and 10-µM treatments with a significant 
depression of GSH pools. Again, normal GSH levels were restored with increasing 
glycidamide concentrations (Fig. 6B). These results indicate that the transcriptional 
induction of key factors responsible for GSH biosynthesis and recycling compensates for 
the partial GSH loss due to S-conjugation with the toxic metabolite. Consistent with its 
more limited transcriptional effects (Fig. 4C), no reparation of the GSH pool was 
observed upon acrylamide treatment of MCF7 (Fig. 6C) or CaCo-2 cells (Fig. 6D). 
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Figure 6. Measurement of GSH pools and NF-!B activity. (A) GSH levels in MCF7 cells 
after 24-h exposures to the indicated glycidamide concentrations. (B) GSH levels in 
CaCo-2 cells following glycidamide treatments. (C) GSH levels in MCF7 cells after 24-h 
exposures to the indicated acrylamide concentrations. (D) GSH levels in CaCo-2 cells 
following acrylamide treatments. All GSH quantifications are shown as the mean of five 
independent measurements. Error bars indicate the standard deviation, asterisks indicate 
values that are significantly different from the unexposed controls (P < 0.05, Mann-
Whitney U test). 
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4.7. NF-!B activation 
 
Glycidamide exposure results in the stimulation of both positive and negative regulators 
of the NF-!B pathway. In fact, the up-regulation of transcripts coding for RANK and 
HNLF, which activate NF-!B, is accompanied by the concomitant overexpression of 
inhibitors of the NF-!B pathway such as OPG or COMMD10 (Table 1C). In view of 
these opposite effects, we performed a functional assay, based on an exogenous reporter 
gene, to determine how the NF-!B status is altered after glycidamide exposure. For that 
purpose, MCF7 cells were transiently transfected with a construct that carries the DNA 
sequence for firefly luciferase under the control of a minimal promoter containing wild-
type NF-!B binding sites (Hassa et al. 2001). This reporter gene assay yielded a dose-
dependent activation of NF-!B in response to glycidamide, with a substantial effect 
already detectable after the 1-µM treatment (Fig. 7A). In time course experiments, NF-
!B activity peaked after 12 h of glycidamide exposure (Fig. 7B). No reporter gene 
induction was detected in the presence of a control vector where the NF-!B binding sites 
had been omitted (data not shown). In summary, this functional assay revealed that the 
stress-induced activation of NF-!B prevails over its negative regulators, thus resulting in 
an increased constitutive activity of this key transcription factor. 
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Figure 7. (A) Reporter gene assay demonstrating NF-!B activation after 12-h treatments 
with glycidamide. The results are shown as the ratio between the reporter gene (firefly 
luciferase) activity and the internal Renilla standard (five independent determinations). 
(B) Time course of NF-!B activation in MCF7 cells treated with 100 µM glycidamide (3 
independent experiments). Error bars = 95% confidence intervals. Asterisks indicate 
values that are significantly different from the unexposed controls (P < 0.05, Mann-
Whitney U test). 
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5.  DISCUSSION 
               
 
Genome-wide transcriptomes have been determined with high-density DNA microarrays 
to monitor the dose-dependent response of human cells to glycidamide, the reactive 
oxidative metabolite generated from acrylamide. It is expected that glycidamide 
concentrations of 10 µM or higher exceed the estimated dose levels that may occur in 
humans. Recent studies have shown that oral administration of a single 0.1 mg/kg 
acrylamide bolus to rodents resulted in blood and tissue peak concentrations of up to 1 
µM glycidamide (Doerge et al. 2005). Here, our quantitative RT-PCR assays 
demonstrated that changes of gene expression with up to 2-fold inductions or repressions 
could be observed following a 1-µM glycidamide treatment, thus approaching the 
concentration range that is relevant for the assessment of human health risks. Examples 
include the induction of transcripts coding for EPHX1 and SLC7A11, involved in 
detoxification processes, or the repression of CDH12 and FHOD3, implicated in tumor 
cell mobility and tissue invasion (Katoh and Katoh 2004). These RT-PCR determinations 
showed that many of the same transcriptional changes also occur in CaCo-2 cells, which 
are used as a surrogate for the human intestinal epithelium. 
 The micromolar doses of glycidamide that induce most of these transcriptional 
responses might still seem too high to be achieved by dietary exposure. However, the 
sensitivity of target cells depends on the capacity of their detoxification systems and, 
considering that the uptake of acrylamide is normally accompanied by other toxic food 
constituents that may saturate the cytoprotective systems, adverse effects are likely to 
occur at even lower concentrations than those expected from threshold experiments 
performed with a single compound. In the case of EPHX1, a significant transcriptional 
induction was observed at a glycidamide level of as low as 0.1 µM, indicating that this 
primary detoxification enzyme represents a sensitive biomarker for glycidamide 
exposure. 
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 The principal advantage of obtaining a broad molecular fingerprint involving multiple 
simultaneous endpoints, as opposed to the determination of a single endpoint, is that the 
cellular response becomes more specific and sensitive. In fact, by screening for sets of 
transcripts that are up- or down-regulated in a coordinated manner, the global expression 
analysis has been shown to generate characteristic molecular signatures that improve the 
overall signal-to-noise ratio, thereby facilitating the assessment of biological effects. 
Even if at the single gene level there are only subtle differences in expression, the 
concordant regulation of multiple transcripts contributing to the same pathway may 
significantly alter cellular functions and, as a consequence, elicit a relevant response 
(Subramanian et al. 2005). By focusing on groups of genes that participate in common 
pathways, the detection of transcriptional patterns in target tissues generates a molecular 
signature that may replace more traditional biomarkers that rely on the measurement of 
macromolecular lesions or metabolic by-products with uncertain significance. 
 Our large-scale transcriptional analysis revealed that three major systems are 
regulated upon glycidamide treatment: detoxification (Table 1A), antioxidant defense 
(Table 1B) and tumor progression (Table 1C). One outstanding response to the oxidative 
imbalance generated by glycidamide is the overexpression of multiple members of the 
GSH pathway. 
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 Figure 8. Scheme illustrating the different members of the GSH system leading to 
acrylamide and glycidamide detoxification that are subjected to transcriptional 
regulation following glycidamide treatment inside a mammalian cell. MGST = 
microsomal glutathione S-transferase; GPX = glutathione peroxidase; ME1 = malic 
enzyme 1; G6PD = glucose-6-phosphate dehydrogenase; GCLM = glutamate-cysteine 
ligase, modifier subunit; SLC7A11 = solute carrier family 7, member A11; N = nucleus, 
C = cytoplasm. 
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As illustrated in Fig. 8, these factors mediate not only GSH biosynthesis (SLC7A11, 
GCLM), but also subsequent conjugation (MGST1, GPX2, GPX3) and recycling steps 
(ME1, G6PD). Direct measurements in both MCF7 and CaCo-2 cells yielded a partial 
GSH depletion after a 24-h incubation with glycidamide, but only at the lower 0.1- or 1-
µM concentration levels. In conjunction with the low-dose EPHX1 induction, this effect 
on the cellular thiol pool suggests a concentration range in which glycidamide is 
effectively inactivated inside the tested human cells. This cytoprotective window 
coincides with the results of the PCA analysis (Fig. 3), which indicates that the 
transcriptome generated by a 1-µM glycidamide treatment displays, in part, a different 
pattern than the profiles induced at higher doses. 
 Additional expression changes are observed at glycidamide concentrations of 10 µM 
or higher. An intriguing response is the up-regulation of several aldo-keto reductases 
(AKR1C1, AKR1C2 and AKR1C3) that have been implicated in breast and prostate 
cancer by virtue of their ability to catalyze the conversion of inactive androgen and 
estrogen precursors to biologically potent steroid hormones such as testosterone, 3!- and 
3"-androstanediol, and 17"-estradiol (Lin et al. 2004). A hormonal activity of acrylamide 
or glycidamide, which may enhance their genotoxic properties, has already been 
discussed in view of the rodent long-term studies yielding tumors in endocrine glands and 
hormone-dependent tissues, including testicular mesotheliomas as well as mammary 
adenomas and carcinomas (Rice 2005). However, no data was provided to support an 
endocrine mode of action for acrylamide or glycidamide. Thus, the present report 
presents the first example of a hormonal dysregulation, involving the up-regulation of 
aldo-keto reductases, that may link acrylamide exposure to the development of tumors in 
steroid-dependent tissues. 
 Many other transcripts positively regulated by glycidamide (at concentrations of 10 
µM or higher) have been associated with cancer progression (see Table 1C). For 
example, osteoprotegerin (OPG) has been reported to represent a survival factor in breast 
cancer tissue by acting as a soluble decoy receptor that blocks apoptosis-inducing signals 
such as TRAIL (Van Poznac et al. 2006). An anti-apoptotic activity has also been 
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attributed to ARC (Neuss et al. 2001). Huntingtin interacting protein 14 (HIP) is a 
palmitoyltransferase enzyme that induces anchorage-independent cell growth (Ducker et 
al. 2004). Cell proliferation may be further stimulated by overexpression of the insulin-
like growth factor (IGF) receptor IGFR2 and the concomitant down-regulation of 
IGFBP2, IGFBP4 and IGFBP5, which are known to attenuate IGF activity. KITLG is 
another growth factor overexpressed in glycidamide-treated cells. METAP2, induced by 
glycidamide exposure, has been associated with the metastatic progression of 
adenocarcinomas (Selvakumar et al. 2004). The high-dose response to glycidamide is 
further characterized by the down-regulation of transcripts coding for cell adhesion 
molecules and many other growth-inhibitory factors (Table 1C). 
 We found that multiple glycidamide-inducible genes code for members of the NF-!B 
pathway, a key mediator of cellular stress responses. A subsequent reporter gene assay in 
MCF7 mammary cells demonstrated that glycidamide treatment increases the constitutive 
activity of the NF-!B complex. NF-!B is known to trigger anti-apoptotic responses 
thereby controlling the ability of tumors to escape apoptosis-based surveillance 
mechanisms. NF-!B has also been implicated in the regulation of cell proliferation, 
angiogenesis, tumor cell migration and invasiveness (Karin 2006). An immediate clinical 
implication of overactive NF-!B complexes is illustrated by the finding that the 
constitutive stimulation of NF-!B is linked to a subset of high-risk breast cancers with 
poor prognosis (Zhou et al. 2006). 
 To conclude, this functional genomic study revealed that glycidamide exerts a 
plethora of transcriptional effects that should be included in risk assessment studies. As a 
consequence, we propose to implement a threshold level that prevents the induction of 
potentially hazardous transcriptional responses mediated by glycidamide in target tissues 
such as the mammary gland or the intestinal epithelium. The results of this in vitro study 
suggest that low-dose responses, primarily the induction of EPHX1, may exert beneficial 
effects by promoting inactivation of the toxicant, and that potentially adverse changes, for 
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example dysregulation of steroid hormone synthesis, are detected at concentrations above 
the range that is relevant for human populations. 
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6.   SIGNIFICANCE 
               
 
Substantial efforts have been made during the last few years to investigate the possible 
hazardous effect of acrylamide occurring in food. A major gap of knowledge was the lack 
of information regarding the non-genotoxic effects of acrylamide in human cells. Thus, 
our aim was to provide the transcriptomic fingerprint induced by acrylamide or its 
metabolite glycidamide to enlighten the mode of action of these compounds and the 
cellular reactions they elicit. 
 Our transcriptomic approach revealed that glycidamide, the oxidative metabolite of 
acrylamide, causes broad alterations of genome function, thereby inducing distinctive 
expression profiles that may modulate the genotoxic effects of this food contaminant. By 
inspection of the dose-dependent cellular reactions, we concluded that low-dose 
responses (primarily the induction of EPHX1) exert beneficial effects by promoting 
inactivation of the toxicant (Fig. 9). Other detoxification processes observed at the low-
dose glycidamide level of 0.1 µM include its inactivation through conjugation with 
glutathione. Adverse effects, such as for example the down-regulation of cell-adhesion 
molecules (CDH12, ANXA1, ITGB6), the up-regulation of factors that lead to 
dysregulation of steroid hormone synthesis (AKR1C2, AKR1C3), or factors that promote 
cell survival and cell cycle progression (NF-!B, RRM2, Cyclin-1, MAPK12) are detected 
at concentrations above the range that appears to be relevant for human populations. An 
induction of the DNA repair enzyme EME1, indicative of the formation of DNA damage, 
is also observed in the upper level of the tested dose range. Thus, the main implication of 
these findings for risk assessment is that transcriptional signatures associated with DNA 
damage or tumor cell progression may be expected only at doses that exceed the range of 
ordinary dietary exposure. 
 These findings indicate that the standard procedure of extrapolating from high-
dose effects in rodents or other experimental systems to the very low-dose level of human 
exposure would lead to an overestimation of the toxicological risk, thus exaggerating the 
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health hazards resulting from the presence of acrylamide in food and its metabolic 
conversion to glycidamide in the human body. 
 
 
 
 
 
Figure 9. Summary of the main findings from the transcriptomic profiling of glycidamide 
effects in human cells. Beneficial responses are observed at the low-dose level, 
potentially hazardous effects are detected at high glycidamide concentrations. 
Abbreviations: EPXH1, epoxide hydrolase-1; GSH, glutathione; FHO3, formin 
homology-3; CDH12, cadherin-12; NF-!B, nuclear factor-!B; RRM2, ribonucleotide 
reductase polypeptide-M2; AKR1C2, aldo-keto reductase-C2; AKR1C3, aldo-keto 
reductase-C3; EME1, essential meiotic endonuclease-1; ANXA1, annexin-A1; ITGB6, 
integrin beta-6; MAPK12, mitogen-activated protein kinase-12. 
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